Michael Overman

41PUBLICATIONS
257CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical infection agents (incl. prions)Predictive and prognostic markersMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Jul 29, 2026
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

|Jul 24, 2026
Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy.

|Nov 18, 2025
Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.

Giulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury

|Nov 14, 2025
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Mohamed E Salem, Alberto Puccini, Elizabeth Mauer

|Jul 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

|Feb 10, 2025
Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors.

Vincenzo Nasca, Joseph Zhao, Javier Ros

Pageof 7

Frequent Collaborators

9 joint publications

Scott Kopetz

9 joint publications

Kanwal Raghav

7 joint publications

N Arvind Dasari

7 joint publications

John Paul Shen